GT
MRVI icon

Glenmede Trust’s Maravai LifeSciences MRVI Stock Holding History

Glenmede Trust’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,240,698
Closed -$12.2M – 1419
2024
Q4 		$12.2M Buy
2,240,698
+14,664
+0.7% +$94.3K 0.06% 326
2024
Q3 		$18.5M Sell
2,226,034
-31,853
-1% -$275K 0.09% 233
2024
Q2 		$16.2M Buy
2,257,887
+13,672
+0.6% +$118K 0.08% 251
2024
Q1 		$19.5M Buy
2,244,215
+161,287
+8% +$1.09M 0.1% 213
2023
Q4 		$13.6M Buy
2,082,928
+974,374
+88% +$6.29M 0.07% 289
2023
Q3 		$11.1M Buy
1,108,554
+688,403
+164% +$7.56M 0.06% 316
2023
Q2 		$5.81M Buy
420,151
+24,716
+6% +$334K 0.03% 396
2023
Q1 		$5.54M Buy
395,435
+369,903
+1,449% +$5.31M 0.03% 400
2022
Q4 		$365K Buy
25,532
+11,934
+88% +$188K ﹤0.01% 923
2022
Q3 		$347K Sell
13,598
-24,376
-64% -$612K ﹤0.01% 910
2022
Q2 		$1.08M Buy
+37,974
New +$1.2M 0.01% 654

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's MRVI Position: Q1 2025 in Review

Glenmede Trust sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 2,240,698 shares — an estimated $12.2M sold.

Glenmede Trust first reported a position in MRVI in Q2 2022 and held it in 11 quarters. The position peaked at $19.5M in Q1 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Glenmede Trust reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Glenmede Trust sold 2,240,698 Maravai LifeSciences shares in Q1 2025, an estimated $12.2M.
  • Glenmede Trust first reported a position in Maravai LifeSciences in Q2 2022 and held it in 11 quarters.
  • Glenmede Trust's Maravai LifeSciences position peaked at $19.5M in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.